To generate the robust clinical evidence necessary to support applications for marketing authorisation of medicinal products intended to treat or prevent COVID-19 multi-centre clinical trials involving several Member States will need to be conducted.
Recital 15, Regulation (EU) 2020/1043
In forcesince 15 Jul 2020